A post-hoc EXSCEL analysis testing whether baseline ejection fraction modifies the effect of once-weekly exenatide on heart failure hospitalisation in type 2 diabetes. PICO summary and expert commentary.
Browsing: GLP-1 Receptor Agonists
A first-in-human phase I trial of the NPY2 receptor agonist BI 1820237, alone or with low-dose liraglutide, in 95 men with overweight or obesity, reporting safety, tolerability, and additive effects on gastric emptying. PICO summary and expert commentary.
A small randomized trial finds baseline IL-1β in mononuclear cells predicts the degree of MASLD improvement after weight loss in obesity with prediabetes or early type 2 diabetes. PICO summary and expert commentary.
A Sanofi-sponsored post hoc analysis of the LixiLan-L-CN trial reports that iGlarLixi lowered residual hyperglycaemia more than insulin glargine alone in Chinese adults with type 2 diabetes. PICO summary and expert commentary.
Exploratory analysis of AMPLITUDE-O finds baseline FIB-4 score is not associated with cardiovascular outcomes and does not modify efpeglenatide’s effect in high-risk type 2 diabetes. PICO summary and expert commentary.
A Phase 2 randomised trial in 145 adults found once-weekly ecnoglutide lowered HbA1c by up to 2.39% versus 0.55% with placebo over 20 weeks. PICO summary and expert commentary.
A small double-blind RCT in 38 patients with type 2 diabetes and coronary disease found pre-operative liraglutide gave better intra-operative glucose control and described regional epicardial fat microRNA patterns. PICO summary and expert commentary.
An RCT finds adding semaglutide to metformin improves weight, testosterone, and natural pregnancy rates in women with PCOS. PICO summary and expert commentary.
An RCT finds the GLP-1 analogue Ebenatide improves glycaemia, time in range, and body composition in type 2 diabetes, confirming a class effect. PICO summary and commentary.
An acute crossover infusion study (n=8) found exenatide-glucagon co-infusion raised myocardial glucose uptake and a diastolic strain rate marker in type 2 diabetes. PICO summary and expert commentary.